MISFIRES aims to guide new academic and policy thinking by establishing how: 1) concerned actors voice and mobilise around the notion that a healthcare market has ‘failed’ them; 2) concerned actors seek to negotiate and address these failures; 3) this process may lead to ‘better’ healthcare markets (as defined by the actors).
The project also explores participatory and collaborative strategies in the five cases it researches by helping to open these markets up to the concerns of those who are let down by them. Individual case studies include issues around the assetization of pharmaceutical patents (Hepatitis C), evolving activist strategies around access to medicines (HIV/AIDS), digital activism and user innovation (Type 1 Diabetes), and the use of participatory tools as a response to non-engagement by publics (private and public genomics initiatives).
Susi Geiger, "MISFIRES and Marketing Innovation - Innovating Together for Better Markets", contributed by , STS Infrastructures, Platform for Experimental Collaborative Ethnography, last modified 31 July 2019, accessed 26 April 2024. https://stsinfrastructures.org/content/misfires-and-marketing-innovation-innovating-together-better-markets
Critical Commentary
MISFIRES aims to guide new academic and policy thinking by establishing how: 1) concerned actors voice and mobilise around the notion that a healthcare market has ‘failed’ them; 2) concerned actors seek to negotiate and address these failures; 3) this process may lead to ‘better’ healthcare markets (as defined by the actors).
The project also explores participatory and collaborative strategies in the five cases it researches by helping to open these markets up to the concerns of those who are let down by them. Individual case studies include issues around the assetization of pharmaceutical patents (Hepatitis C), evolving activist strategies around access to medicines (HIV/AIDS), digital activism and user innovation (Type 1 Diabetes), and the use of participatory tools as a response to non-engagement by publics (private and public genomics initiatives).